AstraZeneca to invest $50bn in US by 2030, boosting medicine manufacturing
The investment supports AstraZeneca's aim to reach $80bn in revenue by 2030, with 50% expected from the US.

A leading resource for the Pharmaceutical industry since 2002
The investment supports AstraZeneca's aim to reach $80bn in revenue by 2030, with 50% expected from the US.
Give your business an edge with our leading industry insights.
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery